Skip to main content

Advertisement

Figure 6 | Molecular Cancer

Figure 6

From: Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response

Figure 6

Phosphorylation statuses of EGFR sites were determined using antibody arrays. Increased phosphorylation of ErbB2(Thr686), ErbB2(Ser1113) and limited phosphorylation of EGFR(Thy845), ErbB2(Tyr1221/1222), ErbB3(Tyr1289) and ErbB4(Tyr1284) sites was seen in the control group. In the monotherapy groups, ErbB2(Thr686), (Ser113) and ErbB4(Tyr1284) sites were phosphorylated. Inhibition of most of the EGFR phosphorylation sites was observed in combination therapy groups except for ErbB2(Thr686) and (Ser1113). (A: Control, B: PDT, C: Erbitux and D: PDT + Erbitux).

Back to article page